Submucosal tissues of warm-blooded vertebrates are useful in tissue grafting materials and have an extensive history of use in surgical applications. In particular, submucosal tissue graft compositions derived from extracellular matrices (ECM), such as urinary bladders, have been described in U.S. Pat. Nos. 5,554,389 and 6,576,265, both incorporated herein by reference. ECM sheet devices are fully-resorbable devices and mitigate the inflammatory response. Importantly, the lack of cross-linking in ECM sheet scaffolds, in contrast to synthetic scaffolds, encourages the repair and remodeling response of damaged tissues post-implantation.
Although ECM devices offer a number of advantages in wound care, physicians are accustomed to working with stronger, permanent devices, such as nylon meshes and polytetrafluoroethylene (PTFE), in surgical applications where suture-retention strength is critical, and are hesitant to use biodegradable ECM devices due to their weaker mechanical properties.
The development of ECM sheet layering has been sufficient to increase the mechanical strength of ECM devices. However, multiple layers in ECM devices decreases the conformability of the ECM device to the underlying tissue at the surgical site. Therefore, a need persists for enhanced, resorbable, ECM sheet devices with strengthened mechanical properties.
The present disclosure describes the selective retention of muscle tissue during ECM processing, either uniformly or regionally across the entire ECM device to increase mechanical strength and decrease failure rates during surgical and wound healing applications. ECM sheet devices allow for better surgical outcomes than permanent scaffolds, due to their mimicry of mammalian tissue during the wound repair response. Stronger ECM devices also permit ECM to be used in additional surgical applications, such as suture retention strength and to correct bridging defects, which require higher mechanical strength.
To produce extant ECM devices, mammalian tissues are skinned, removing the epithelial layer, and delaminated removing the majority of the muscle tissue.
In contrast, in some embodiments of the present disclosure, the mammalian tissue is not delaminated and the resulting ECM retains residual muscle tissue, enabling ECM devices to retain mechanical strength.
In some embodiments, to retain residual muscle tissue during urinary bladder matrix (UBM) production, harvested porcine bladders go through thawing and preparation, and are subsequently skinned, but do not undergo muscle delamination. In fact, production of UBM from bladders in which the muscle layers were not delaminated was shown to be more time and material efficient and generated less waste than production of UBM in which the muscle tissue was delaminated. Retention of muscle tissue in UBM is also advantageous in that it does not require the use of new reagents, chemical, or additives.
To produce ECM sheets, tissues may also undergo differential scraping in specific regions of the sheet. ECM that are differentially scraped can be layered onto muscle-delaminated ECM sheets, other differentially scraped ECM, or ECM retaining residual muscle tissue. Subsequent processing such as disinfection, decellularization, and lamination occur after the sheet device is configured.
ECM sheets retaining muscle tissue may also be cut into desired reinforcement shapes, such as a frame or strips to reinforce the ECM device as needed for a tissue healing application. These ECM shapes may be layered onto other ECM sheets during the lamination process in order to create the final ECM sheet devices.
In examples, extracellular matrix (ECM) sheet compositions of the present disclosure include at least a decellularized basement membrane, lamina propria, and muscle tissue, wherein an ECM sheet is differentially scraped of the muscle tissue. In some examples, the ECM sheet is layered or stacked with at least one additional ECM sheet.
In some examples, the at least one additional ECM sheet is selected from the group of muscle delaminated ECM sheets, additional differentially scraped ECM sheets, and ECM sheets wherein the residual muscle tissue is fully retained.
In further examples, the ECM sheet is cut into reinforcement shapes, optionally wherein the shapes are frames and/or strips, optionally wherein the frames and/or strips are differentially scraped of muscle tissue in a width of at least 0.1%, 1.0%, 5%, 10%, or 50% of the ECM sheet long-axis diameter, optionally wherein the ECM sheets are scraped of muscle tissue in a pattern selected from the group comprising a straight line, a diagonal line, cross-hatching pattern, and/or circular patterns, optionally wherein the scraping pattern contributes increased mechanical strength to the ECM.
In some examples, the ECM sheets are stacked or staggered in configurations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 16, 17, 18, 19 or 20 layers.
In further examples, the one or more ECM sheets is derived from one or more of the following mammalian tissues: urinary bladder matrix (UBM), small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach, and dermis.
In some examples, the ECM sheet composition comprises at least two muscle delaminated ECM sheets on the top and bottom of the sheet stack, and the composition further comprises at least one differentially scraped ECM sheet or strip.
Examples of a method of making an extracellular matrix (ECM) sheet composition of the present disclosure include removing the surface epithelium of a mammalian tissue to form a de-cellularized tissue having an epithelial basement membrane, lamina propria, and muscle tissue, and scraping the muscle tissue into a pattern.
In further examples, the method of making the ECM sheet composition of the present disclosure provides increased mechanical strength relative to ECM sheet compositions containing no muscle tissue. In some examples, the method of making the ECM sheet composition includes stacking or staggering ECM sheets in configurations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 layers. In some examples, the method of making further includes vacuum drying, lyophilization, vacuum pressing and/or air drying. In some examples, the method of making the ECM sheet compositions employs mammalian urinary bladder matrix (IJBM), small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and/or dermis.
Examples of a method of repairing defects of mammalian tissue of the present disclosure include applying one or more ECM sheet compositions differentially scraped of muscle tissue to a mammalian subject, optionally as a treatment for wound healing, and/or in surgical applications. In example, two or more ECM sheets that are layered and laminated may be scraped of muscle tissue in the same scraping pattern and/or extent or in different scraping patterns and/or extents.
Reference to the detailed description, in conjunction with the following figures, will make the disclosure more fully understood, wherein:
In the description that follows, like components have the same reference numerals, regardless of whether they present in different examples. To illustrate examples in a clear and concise manner, the drawings may not necessarily illustrate scale and may show certain features in somewhat schematic form. Features described and/or illustrated with respect to one example may exist in the same way or in a similar way in one or more other examples and/or in combination with or instead of the features of the other examples.
As used in the specification and claim for the purposes of describing and defining the invention, the terms “about” and “substantially” represent the inherent degree of uncertainty attributed to any quantitative comparison, value, measurement, or other representation. The terms “about” and “substantially” also represent the degree by which a quantitative representation may vary from a stated reference without resulting in a change in the basic function of the subject matter at issue. “Comprise”, “include”, “have,” and variations of each word include the listed parts and can include additional parts not listed. “And/or” includes one or more of the listed parts and combinations of the listed parts. The terms “upper”, “lower”, “left”, “right” and the like serve to clearly describe the disclosure but do not limit the structure, positioning and/or operation of the disclosure in any manner.
In the instant disclosure, “skinned” tissue refers to tissue wherein the superficial epithelial layer is removed. In some embodiments, the urothelial layer is removed.
In the instant disclosure, the “extracellular matrix” or “ECM” refers to mammalian tissue which has been skinned, removing the superficial epithelial layer, and which comprises at least the basement membrane and lamina propria. In some embodiments the ECM comprises residual muscle tissue including but not limited to the submucosa, the muscularis externa, and/or the tunica serosa, optionally wherein the residual muscle tissue is differentially scraped. In some embodiments the ECM is decellularized. In some embodiments, the ECM is derived from urinary bladder. In other embodiments, the ECM is derived from small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and/or dermis.
In the instant disclosure, “delaminated” refers to full removal of muscle tissue layers including for example, the submucosa, the muscularis externa, and/or the tunica serosa.
In the instant disclosure, “decellularized” refers to removal of cells from a tissue, by any method known in the art, such as methods comprising disinfectants or acidic solutions to produce a decellularized extracellular matrix (ECM) scaffold. In some preferred embodiments, the decellularized ECM encourages the repair and remodeling of damaged tissues post-implantation.
In the instant disclosure, “basement membrane” refers to a thin, pliable sheet-like matrix, that provides cell and tissue support. The basement membrane is between epithelial tissues and the underlying connective tissue.
In the instant disclosure, “lamina propria” refers to a loose connective tissue supporting the mucosal epithelium. Compared to other loose connective tissue, lamina propria in vivo is relatively cellular.
In the instant disclosure, “muscle tissue,” “muscle layers,” or “muscle” refers to the smooth muscle layer in the walls of organs including but not limited to the bladder, bronchi, intestines, and blood vessels. In some embodiments the muscle tissue may include the submucosa, the muscularis externa, and/or the tunica serosa.
In the instant disclosure, “residual muscle tissue” refers to the muscle tissue remaining on mammalian-derived ECM after skinning. The residual muscle tissue may be fully (delaminated) or differentially scraped, or fully retained. In some embodiments, the residual muscle tissue provides increased mechanical strength to the ECM relative to ECM without muscle tissue. In some embodiments, the ECM comprising residual muscle tissue is derived from a urinary bladder, i.e., urinary bladder matrix (UBM). In some embodiments, the ECM is derived from small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and/or dermis.
In the instant disclosure, “reinforcement shape” refers to cutting the ECM, optionally containing residual muscle tissue into any shape that may be then layered onto additional ECM sheets to produce an ECM sheet device. Examples include frames, strips, squares or other desired shapes. ECM in such shapes may be fully or partially scraped of residual muscle tissue.
In the instant disclosure, a “urinary bladder matrix” or “UBM” refers to a urinary bladder that is opened, stretched, and skinned wherein the superficial urothelial layer and the majority of the muscle tissue is removed, thereby leaving a residual layer of muscle tissue. The residual layer of muscle tissue is scraped into differential patterns.
In some embodiments, an “extracellular matrix sheet device,” “ECM device” or “ECM sheet device” is a single ECM sheet. In some embodiments, multiple ECM sheets are stacked and/or staggered in configurations of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 layers. Multiple layers of ECM sheets may include combinations of layers that partially or fully retain muscle tissue or which contain no residual muscle tissue. For example, UBM sheet compositions of the present disclosure may comprise 3, 4, 5, 6, 7, or 8 layers of stacked or staggered skinned UBM sheets, or alternating skinned UBM sheets and laminated UBM sheets, or any other layering sequence.
In the instant disclosure, ECM sheet devices may be used to repair defects of mammalian tissue including wound healing and surgical applications. In some embodiments, ECM sheets are used to treat pressure ulcers, venous ulcers, diabetic ulcers, and/or chronic vascular ulcers. In some embodiments, ECM sheets may be used to treat tunneled or undermined wounds. In some embodiments, ECM sheets may be used to treat surgical wounds including but not limited to wounds resulting from donor sites or grafts, post-Mohs surgery, post-laser surgery, podiatric, and/or wound dehiscence. In some embodiments, ECM sheets may be used to treat trauma wounds including but not limited to abrasions, lacerations, second-degree burns, and skin tears, and draining wounds. In some embodiments, ECM sheets may be used to reinforce soft tissue during or after gastroenterological and plastic and reconstructive surgery, including but not limited to, open or laparoscopic procedures, hernia, e.g. hiatal and/or diaphragmatic, body wall repair, colon and rectal prolapse repair, tissue repair, urological repair, esophageal repair, and breast reconstruction. In some embodiments, ECM sheets may be used to minimize tissue attachment to a therapeutic device, e.g. in the case of direct contact with viscera. In some embodiments, ECM sheets may be used to treat to facilitate tissue healing in a mammal during or after surgery wherein mechanical strength is required, e.g. to repair or prevent bridging tissue defects.
In the instant disclosure, “suture retention strength” refers to the resistance of an ECM sheet against the pull-out of a suture. Resistance may be measured by pulling the suture with a constant deformation rate until pull-out of the suture from the scaffold occurs. In some embodiments, the suture strength is measured on INSTRON® tensile testing equipment.
In the instant disclosure, “stacked” and “staggered” refers to any configuration of sheets wherein the UBM sheets may overlap one another completely or partially.
In the instant disclosure, “differentially scraped” refers to scraping residual muscle tissue of an ECM sheet after skinning such that not all of the muscle tissue is removed. In some embodiments, the scraping forms a pattern. In some embodiments, the pattern is one of those embodiments A-F illustrated in
In some embodiments the percent residual muscle tissue remaining on the ECM sheet after scraping is at least at least 0.01%, at least 0.1%, at least 0.5%, at least I %, at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or at least 99% of the residual muscle tissue present before scraping. In addition, some embodiments include a range of percent residual muscle tissue remaining on the ECM sheet that is a range between any two of the aforementioned percentages. In further embodiments, the percent residual muscle tissue remaining on the ECM sheet is any and all values contained within the ranges between any two of the aforementioned percentages.
In the instant disclosure, “dried” or “drying” of an ECM sheet refers to any method known in the art to dry ECM sheets including but not limited to vacuum drying, lyophilization, and/or air drying. In some embodiments, drying methods serve to compress the ECM sheets.
In the instant disclosure, “disinfected and rinsed” refers to ECM sheet device production wherein the ECM sheet devices are disinfected through any method known in the art, e.g. with disinfectants or acidic solutions, to rid the device of any pathogens, and subsequent rinsing of the disinfectant.
In the instant disclosure, “lamination” refers to lamination of the final ECM sheet device configuration. The term “laminate” describes both the process and the end result of two or more independent pieces of tissue bonding together. Thus, lamination produces a directed area of connection between the tissues that would not occur unless intentionally created.
In
In
Mechanical and DNA testing of UBM sheet configurations comprising fully delaminated sheets versus sheet configurations comprising residual muscle tissue was performed. It was found that UBM retaining residual muscle tissue did not have significantly increased DNA content compared to fully delaminated UBM, as shown by picogreen DNA assays in
Further, although the tensile strength (
Current UBM surgical products referred to as GENTRIX® Surgical Matrix, comprising delaminated UBM sheets are available in various configurations, including 3, 6, or 6 layers stacked and 8 layers staggered, vacuum pressed to bond the layers together. Vacuum pressing comprises compressing hydrated, remoldable material while subjecting the material to a vacuum. Vacuum pressing can laminate multiple layers of ECM material together by crushing the matrix structure of the ECM. Lyophilization may also be used to produce the final product with multiple layers. The UBM sheet compositions of the instant disclosure, wherein residual muscle tissue is retained on at least one sheet, alone and in various combinations (e.g. multiple layered, stacked and/or staggered in varying degrees and patterns) can address any suture pull through problems associated with the current products, and any other need for enhanced, resorbable, ECM sheet devices with strengthened mechanical properties.
One skilled in the art will realize the disclosure may embody other specific forms without departing from the spirit or essential characteristics thereof. The foregoing examples in all respects illustrate rather than limit the disclosure described herein. The appended claims, rather than the foregoing description, thus indicate the scope of the disclosure, and embrace all changes that come within the meaning and range of equivalency of the claims.
This application claims priority to and benefit under 35 U.S.C. 119(e) to U.S. Provisional Application No. 63/131,600, filed Dec. 29, 2020, the entire contents of which are incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
4902508 | Badylak et al. | Feb 1990 | A |
4956178 | Badylak et al. | Sep 1990 | A |
4978668 | Babbs et al. | Dec 1990 | A |
5007927 | Badylak et al. | Apr 1991 | A |
5275826 | Badylak et al. | Jan 1994 | A |
5281422 | Badylak et al. | Jan 1994 | A |
5354274 | Demeter et al. | Oct 1994 | A |
5372821 | Badylak et al. | Dec 1994 | A |
5445833 | Badylak et al. | Aug 1995 | A |
5516533 | Badylak et al. | May 1996 | A |
5554389 | Badylak et al. | Sep 1996 | A |
5573784 | Badylak et al. | Nov 1996 | A |
5641518 | Badylak et al. | Jun 1997 | A |
5645860 | Knapp et al. | Jul 1997 | A |
5695998 | Badylak et al. | Dec 1997 | A |
5711969 | Patel et al. | Jan 1998 | A |
5753267 | Badylak et al. | May 1998 | A |
5755791 | Whitson et al. | May 1998 | A |
5762966 | Knapp et al. | Jun 1998 | A |
5866414 | Badylak et al. | Feb 1999 | A |
5885619 | Patel et al. | Mar 1999 | A |
5955110 | Patel et al. | Sep 1999 | A |
5968096 | Whitson et al. | Oct 1999 | A |
5997575 | Whitson et al. | Dec 1999 | A |
6096347 | Geddes et al. | Aug 2000 | A |
6099567 | Badylak et al. | Aug 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6187039 | Hiles et al. | Feb 2001 | B1 |
6206931 | Cook et al. | Mar 2001 | B1 |
6241981 | Cobb et al. | Jun 2001 | B1 |
6331319 | Badylak et al. | Dec 2001 | B1 |
6358284 | Fearnot et al. | Mar 2002 | B1 |
6375989 | Badylak et al. | Apr 2002 | B1 |
6379710 | Badylak et al. | Apr 2002 | B1 |
6475232 | Babbs et al. | Nov 2002 | B1 |
6485723 | Badylak et al. | Nov 2002 | B1 |
6576265 | Spievack | Jun 2003 | B1 |
6579538 | Spievack | Jun 2003 | B1 |
6653291 | Badylak et al. | Nov 2003 | B1 |
6696074 | Dai et al. | Feb 2004 | B2 |
6696270 | Badylak et al. | Feb 2004 | B2 |
6783776 | Spievack | Aug 2004 | B2 |
6793939 | Badylak et al. | Sep 2004 | B2 |
6849273 | Spievack | Feb 2005 | B2 |
6852339 | Spievack | Feb 2005 | B2 |
6861074 | Spievack | Mar 2005 | B2 |
6869619 | Spievack | Mar 2005 | B2 |
6887495 | Spievack | May 2005 | B2 |
6890562 | Spievack | May 2005 | B2 |
6890563 | Spievack | May 2005 | B2 |
6890564 | Spievack | May 2005 | B2 |
6893666 | Spievack | May 2005 | B2 |
6969523 | Mattern et al. | Nov 2005 | B1 |
7087089 | Patel et al. | Aug 2006 | B2 |
7354702 | Dai et al. | Apr 2008 | B2 |
7452371 | Pavcnik et al. | Nov 2008 | B2 |
7485138 | Fearnot et al. | Feb 2009 | B2 |
7597710 | Obermiller | Oct 2009 | B2 |
7652077 | Cook et al. | Jan 2010 | B2 |
7745217 | Patel et al. | Jun 2010 | B2 |
7771717 | Badylak et al. | Aug 2010 | B2 |
7776596 | Badylak et al. | Aug 2010 | B2 |
7795022 | Badylak et al. | Sep 2010 | B2 |
7795027 | Hiles | Sep 2010 | B2 |
7815923 | Johnson et al. | Oct 2010 | B2 |
7897167 | Armstrong et al. | Mar 2011 | B2 |
7914567 | Pavcnik et al. | Mar 2011 | B2 |
7959554 | McAlexander et al. | Jun 2011 | B2 |
7993679 | Ingram et al. | Aug 2011 | B2 |
8187619 | Johnson | May 2012 | B2 |
8192763 | Johnson | Jun 2012 | B2 |
8211168 | Purdy et al. | Jul 2012 | B2 |
8298586 | Bosley et al. | Oct 2012 | B2 |
8357402 | Ingram et al. | Jan 2013 | B2 |
8409625 | Badylak et al. | Apr 2013 | B2 |
8444687 | Pavcnik et al. | May 2013 | B2 |
8454678 | Hiles | Jun 2013 | B2 |
8455008 | Johnson | Jun 2013 | B2 |
8535349 | Chen et al. | Sep 2013 | B2 |
8541032 | Bosley et al. | Sep 2013 | B2 |
8541372 | Shah et al. | Sep 2013 | B2 |
8557277 | Virkler et al. | Oct 2013 | B2 |
8591930 | Hiles et al. | Nov 2013 | B2 |
8647677 | Badylak et al. | Feb 2014 | B2 |
8652191 | Fearnot et al. | Feb 2014 | B2 |
8652500 | Bosley et al. | Feb 2014 | B2 |
8658196 | Janis | Feb 2014 | B2 |
8663086 | Duncan et al. | Mar 2014 | B2 |
8716227 | Cook et al. | May 2014 | B2 |
8741352 | Hodde et al. | Jun 2014 | B2 |
8784889 | Hodde et al. | Jul 2014 | B2 |
8790414 | O'Brien et al. | Jul 2014 | B2 |
8802436 | Kentner et al. | Aug 2014 | B1 |
8808352 | Eells et al. | Aug 2014 | B2 |
8835174 | Fette et al. | Sep 2014 | B2 |
8840917 | Armstrong et al. | Sep 2014 | B2 |
8846060 | Archibald et al. | Sep 2014 | B2 |
8895304 | Ette et al. | Nov 2014 | B2 |
8915941 | Obermiller et al. | Dec 2014 | B2 |
8927003 | Badylak et al. | Jan 2015 | B2 |
8932805 | Brahm | Jan 2015 | B1 |
8962035 | Bosley et al. | Feb 2015 | B2 |
8968761 | Bosley et al. | Mar 2015 | B2 |
8975075 | Fette et al. | Mar 2015 | B2 |
9011895 | Dai et al. | Apr 2015 | B2 |
9044455 | Shah et al. | Jun 2015 | B2 |
9056078 | Bosley et al. | Jun 2015 | B2 |
9084722 | Gilbert et al. | Jul 2015 | B2 |
9113851 | Agnew | Aug 2015 | B2 |
9119831 | Kentner et al. | Sep 2015 | B2 |
9138445 | Hodde | Sep 2015 | B2 |
9149262 | Obermiller et al. | Oct 2015 | B2 |
9186435 | Hiles | Nov 2015 | B2 |
9226736 | Obermiller et al. | Jan 2016 | B2 |
9238091 | Kentner et al. | Jan 2016 | B2 |
9254188 | Dempsey | Feb 2016 | B2 |
9265860 | Spievack | Feb 2016 | B2 |
9295757 | Patel et al. | Mar 2016 | B2 |
9404077 | Fette et al. | Aug 2016 | B2 |
9433701 | Spievack | Sep 2016 | B2 |
9456813 | Obermiller et al. | Oct 2016 | B2 |
9456815 | Armstrong et al. | Oct 2016 | B2 |
9474514 | Agnew et al. | Oct 2016 | B2 |
9474829 | Kentner et al. | Oct 2016 | B2 |
9480771 | Fette et al. | Nov 2016 | B2 |
9492149 | Obermiller et al. | Nov 2016 | B2 |
9492267 | Hiles | Nov 2016 | B2 |
9498327 | Brahm | Nov 2016 | B1 |
9504769 | Hiles et al. | Nov 2016 | B2 |
9538996 | Patel et al. | Jan 2017 | B2 |
9561307 | Bosley et al. | Feb 2017 | B2 |
9572556 | Obermiller et al. | Feb 2017 | B2 |
9579183 | Bosley et al. | Feb 2017 | B2 |
9585983 | Brahm | Mar 2017 | B1 |
9687215 | Obermiller et al. | Jun 2017 | B2 |
9764056 | Fette et al. | Sep 2017 | B2 |
9788821 | Johnson et al. | Oct 2017 | B2 |
9789138 | Brahm et al. | Oct 2017 | B1 |
9795638 | Brahm | Oct 2017 | B1 |
9795639 | Brahm | Oct 2017 | B1 |
9795713 | Kentner et al. | Oct 2017 | B2 |
9839721 | Mohan et al. | Dec 2017 | B2 |
9855301 | Brahm | Jan 2018 | B1 |
9861517 | Pavcnik et al. | Jan 2018 | B2 |
9919078 | Brahm | Mar 2018 | B1 |
9931439 | Fearnot et al. | Apr 2018 | B2 |
9956315 | Patel et al. | May 2018 | B2 |
9993506 | Brahm | Jun 2018 | B1 |
9999707 | Gilbert et al. | Jun 2018 | B2 |
10010659 | Brahm et al. | Jul 2018 | B1 |
10016459 | Brahm | Jul 2018 | B1 |
10071187 | Hiles et al. | Sep 2018 | B2 |
10092678 | Spievack | Oct 2018 | B2 |
10245349 | Brahm | Apr 2019 | B2 |
10265438 | Brahm | Apr 2019 | B1 |
10342523 | Obermiller et al. | Jul 2019 | B2 |
10470749 | Obermiller et al. | Nov 2019 | B2 |
10471182 | Hiles et al. | Nov 2019 | B2 |
10500309 | Shah et al. | Dec 2019 | B2 |
10517994 | Bosley et al. | Dec 2019 | B2 |
10555974 | Brahm | Feb 2020 | B1 |
10568914 | Brahm | Feb 2020 | B1 |
10688219 | Patel et al. | Jun 2020 | B2 |
10786600 | Brahm | Sep 2020 | B1 |
10806833 | Pomrink et al. | Oct 2020 | B1 |
10898610 | Bosley et al. | Jan 2021 | B2 |
10905798 | Brahm | Feb 2021 | B1 |
10905800 | Brahm | Feb 2021 | B1 |
11000628 | Bosley et al. | May 2021 | B2 |
11013829 | Bosley et al. | May 2021 | B2 |
11026667 | Agnew et al. | Jun 2021 | B2 |
11064987 | Obermiller et al. | Jul 2021 | B2 |
11065368 | Peck et al. | Jul 2021 | B2 |
11077229 | Brahm | Aug 2021 | B1 |
11077231 | Hiles et al. | Aug 2021 | B2 |
11167061 | Brahm | Nov 2021 | B1 |
11173231 | Hiles et al. | Nov 2021 | B2 |
11185611 | Gilbert et al. | Nov 2021 | B2 |
11224616 | Brahm | Jan 2022 | B1 |
11224617 | Brahm | Jan 2022 | B1 |
20040043006 | Badylak et al. | Mar 2004 | A1 |
20040078076 | Badylak et al. | Apr 2004 | A1 |
20040187877 | Badylak et al. | Sep 2004 | A1 |
20050143807 | Pavcnik et al. | Jun 2005 | A1 |
20050182484 | Patel et al. | Aug 2005 | A1 |
20060136047 | Obermiller et al. | Jun 2006 | A1 |
20060251702 | Janis et al. | Nov 2006 | A1 |
20070166395 | McAlexander | Jul 2007 | A1 |
20070179507 | Shah | Aug 2007 | A1 |
20070184122 | Johnson et al. | Aug 2007 | A1 |
20080167728 | Cook et al. | Jul 2008 | A1 |
20090318934 | Johnson et al. | Dec 2009 | A1 |
20110060362 | Patel et al. | Mar 2011 | A1 |
20150258142 | Dhanaraj | Sep 2015 | A1 |
20160089477 | Valmikinathan et al. | Mar 2016 | A1 |
20160206785 | Patel et al. | Jul 2016 | A1 |
20170072099 | Hiles et al. | Mar 2017 | A1 |
20170086808 | Patel et al. | Mar 2017 | A1 |
20180036451 | Fette et al. | Feb 2018 | A1 |
20180043057 | Kentner et al. | Feb 2018 | A1 |
20180228939 | Hiles et al. | Aug 2018 | A1 |
20180280574 | Gilbert et al. | Oct 2018 | A1 |
20190046211 | Bronikowski et al. | Feb 2019 | A1 |
20190336650 | Hiles et al. | Nov 2019 | A1 |
20200129666 | Bosley et al. | Apr 2020 | A1 |
20200188559 | Hiles et al. | Jun 2020 | A1 |
20200316257 | Patel et al. | Oct 2020 | A1 |
20210077661 | Valmikinathan et al. | Mar 2021 | A1 |
20210308342 | Peck et al. | Oct 2021 | A1 |
Entry |
---|
US 7,608,454 B2, 10/2009, Badylak et al. (withdrawn) |
Number | Date | Country | |
---|---|---|---|
63131600 | Dec 2020 | US |